At the start of the new year, we executed an exclusive option agreement with the MD Anderson Cancer Center for a lung cancer blood test developed by one of the country's leading experts in early cancer detection. The MD Anderson team lead by Sam Hanash, MD, Ph.D. has received over $50 million in funding from federal and state government and philanthropies in support of this test. Validated using blood specimens from about one million pre-symptomatic individuals, the blood test analyzes several of the same tumor antigens that are part as 20/20's multi-cancer test along with one novel biomarker (ProSurfactant B) discovered by that team. The main purpose of the test is to screen individuals with a history of tobacco use for lung cancer risk.

Additional information about the MD Anderson lung cancer test can be gleaned from this video, blog, or their latest peer-reviewed publication.

Early investors in 20/20 will recall our PAULA's test for lung cancer marketed between 2012 and 2015 that, like the MD Anderson test, was based on tumor antigens in the blood. We believe that the addition of the novel biomarker coupled with the extensive validation by the Hanash team will give this test new momentum, especially in light of recent campaigns by the American Lung Association and others to promote lung screening to those with a smoking history.

The global multi cancer early detection market size is estimated to reach around $2.9 billion by 2030 according to a recent report issued by Vision Research. This is in line with 20/20's own estimates that the MCED market in the U.S. alone will exceed $1.6 billion by the end of this decade if even 20% of middle-aged adults obtain these tests in 2030.

A bipartisan bill in Congress to make it easier for Medicare and Medicaid and to cover MCEDs had 257 Cosponsors at the end of the 117th Congress. With nearly half of all Senators and Representatives signing on as co-sponsors, it is likely that this bill will pass in the current Congress.

This month, we initiated a relationship with the pharmacy division of Giant Food to make available to their shoppers lab based Covid PCR testing. Take home collection kits will be distributed and collected at 25 Giant stores throughout the Washington D.C. metropolitan area and transported to our CLIA lab for analysis. The parties are also discussing the possibility of making available to pharmacy patrons other lab tests for early disease detection, wellness, and nutrition.

Giant is part of Ahold Delhaize, one of the world's largest food retail groups with brands such as Food Lion, Stop & Shop, and Hannaford that serve more than 55 million shoppers each week in the U.S. and Europe.

In December the company received a Notice of Allowance from the U.S. Patent & Trademark Office with respect to a pending patent application titled "Methods and Machine Learning Systems for Predicting the Likelihood or Risk of Having Cancer." The patent, which is expected to issue during the 1st quarter of this year, is the first covering its OneTest multi-cancer early detection blood test. Additional patent applications covering this product are pending in the U.S. and around the world.

At the start of the New Year our company named David Lees as our Director of Sales. Between 2019 and 2021 David served as one of our company's first and best performing Sales Representatives. In 2022 he left 20/20 to join one of the world's leading software providers becoming that company's top performing salesperson in his division. We are excited to have David join our team again in his new role.

In order to maintain our Reg. A+ Qualification we are required to file Annual and Semiannual Reports with the U.S. Securities & Exchange Commission (SEC) that include Financial Statements (the Annual Statement must be audited). Those reports may be accessed by entering "20/20 GeneSystems, Inc." at https://www.sec.gov/edgar/searchedgar/companysearch.html or by contacting investors@2020gene.com